Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Advisory Services Network LLC

Advisory Services Network LLC cut its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 57.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 79,066 shares of the biotechnology company's stock after selling 105,295 shares during the quarter. Advisory Services Network LLC owned about 0.06% of Aurinia Pharmaceuticals worth $710,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $25,000. Blue Trust Inc. grew its position in Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 6,174 shares during the last quarter. FMR LLC increased its stake in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 3,919 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $96,000. Finally, Union Bancaire Privee UBP SA acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $108,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Insider Activity

In related news, CEO Peter Greenleaf sold 195,593 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the transaction, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. The trade was a 9.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Greg Keenan sold 12,239 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the completion of the sale, the insider now directly owns 161,789 shares in the company, valued at approximately $1,294,312. The trade was a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 343,898 shares of company stock valued at $2,753,094 in the last ninety days. Insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH traded up $0.09 during trading hours on Friday, reaching $7.76. The stock had a trading volume of 929,141 shares, compared to its average volume of 1,350,101. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.77 and a 52-week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market cap of $1.07 billion, a P/E ratio of -51.74 and a beta of 1.20. The stock has a fifty day moving average of $7.99 and a 200 day moving average of $8.12.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.